New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
04:55 EDTSNE, SNE, SNE, SNE, SNE, SCMP, SCMP, SCMP, SCMP, SCMP, PRGO, PRGO, PRGO, PRGO, PRGO, OMER, OMER, OMER, OMER, OMER, NBY, NBY, NBY, NBY, NBY, LMNS, LMNS, LMNS, LMNS, LMNS, HALO, HALO, HALO, HALO, HALO, CAJ, CAJ, CAJ, CAJ, CAJ, AKRX, AKRX, AKRX, AKRX, AKRX, AGN, AGN, AGN, AGN, AGN, ACL, ACL, ACL, ACL, ACL, ABT, ABT, ABT, ABT, ABTAmerican Society of Cataract and Refractive Surgery to hold a symposium
2014 ASCRS-SOA Symposium & Congress is being held in Boston, MA on April 25-29.
News For ABT;ACL;AGN;AKRX;CAJ;HALO;LMNS;NBY;OMER;PRGO;SCMP;SNE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 18, 2015
11:07 EDTOMEROmeros price target raised to $75 from $60 at WBB Securities
Subscribe for More Information
10:07 EDTOMERHigh option volume stocks
High option volume stocks: CCOI XONE XDE OMER JMBA URBN W SCCO DKS ESPR FEYE W
09:23 EDTOMEROn The Fly: Pre-market Movers
Subscribe for More Information
07:08 EDTOMEROmeros currently completing third and final cohort trial for OMS721
Omeros announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies, or TMAs. TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi in the microcirculation of the body's organs. The Phase 2 trial is designed to enroll primarily aHUS patients but can also enroll patients with thrombotic thrombocytopenic purpura, or TTP and hematopoietic stem cell transplant, or HSCT-related TMA. The trial has fully enrolled the first and second cohorts and is currently completing the third and final planned cohort of its dose-ranging stage. In each three-patient cohort, OMS721 is dosed for four weeks. Today the company is releasing data from its second cohort and data to date from its third cohort. Three patients were treated in the second or mid-dose cohort, two of whom have aHUS and one with TTP. Both patients with aHUS were on renal dialysis prior to and at the time of study enrollment. Based on the positive data from the mid-dose cohort, the high-dose cohort was initiated and an aHUS patient has already completed the study treatment period. No patient with HSCT-related TMA has yet completed dosing with OMS721. The data referenced for all patients include measures to one week following the last dose.
August 17, 2015
07:03 EDTOMEROmeros announces plan to file infringement suit against ANDA filer
Subscribe for More Information
August 14, 2015
17:32 EDTAGNPershing Square gives quarterly update on stakes, liquidates Allergan position
Subscribe for More Information
17:08 EDTAGNPaulson & Co gives quarterly update on stakes
Subscribe for More Information
16:44 EDTPRGOThird Point gives quarterly update on stakes
NEW STAKES: Baxter (BAX), T-Mobile (TMUS), Sealed Air (SEE), Devon (DVN), and Perrigo (PRGO). INCREASED STAKES: SunEdison (SUNE), Dow Chemical (DOW), Mohawk (MHK), Yum! Brands (YUM), and IAC/InterActiveCorp (IACI). DECREASED STAKES: Ally Financial (ALLY), Amgen (AMGN), Sensata (ST), Masco (MAS), and Delta (DAL). LIQUIDATED STAKES: Dollar General (DG), McKesson (MCK), Edgewell Personal Care (EPC), Maxim (MXIM), and FleetCor (FLT).
15:33 EDTAGNEndo confirms court ruling upholding OPANA ER intellectual property
Subscribe for More Information
14:15 EDTAGNEndo successful in blocking Opana generic until 2023, Bloomberg reports
Subscribe for More Information
13:33 EDTPRGOPaulson & Co. votes in support of Mylan's proposed merger with Perrigo
Subscribe for More Information
12:12 EDTPRGOPaulson recently took position in Perrigo, WSJ reports
John Paulson's hedge fund, which owns a 4.6% stake in Mylan (MYL), recently built a position in Perrigo (PRGO), Wall Street Journal reports, citing people familiar with the matter. Mylan has made an unsolicited bid to acquire Perrigo. Shares of Perrigo moved up following the report, and sit up 85c to $193.35 in midday trading.
11:10 EDTPRGOPerrigo says ISS affirms position that Mylan deal would be 'value destructive'
Subscribe for More Information
09:20 EDTPRGOMylan responds to ISS recommendation regarding Perrigo transaction
Subscribe for More Information
08:59 EDTPRGOMylan tells holders board unanimously recommends Perrigo deal
Subscribe for More Information
08:35 EDTPRGOHayman takes Mylan, Perrigo stakes, boasts exposure to energy
Subscribe for More Information
08:23 EDTPRGOMylan still in 'decent' position to win Perrigo vote, CNBC's Faber reports
Subscribe for More Information
08:22 EDTPRGOISS tells Mylan investors to vote against Perrigo takeover, WSJ reports
Proxy adviser Institutional Shareholder Services, or ISS, recommended that Mylan (MYL) investors vote against approving the company's $36B takeover of Perrigo (PRGO), the Wall Street Journal reports. ISS said that the deal faces too many hurdles and has "unreasonable uncertainties" associated with it, the report says. Reference Link
07:37 EDTAGNJANA reports new stakes in Allergan, TWC, sells Applied Materials
Subscribe for More Information
07:12 EDTSNESony's Playstation 4 leads in strong July video game sales, VentureBeat reports
Even though July brought few major video game releases, new game hardware, software, and accessories generated $541.9M at U.S. retailers in the month, up 6% year over year, VentureBeat reports, citing data from NPD Group. Sony's (SNE) Playstation 4 console outsold its competitors' consoles, namely Nintendo's (NTDOY) Wii U and Microsoft's (MSFT) Xbox One, the report says. Reference Link
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use